ACUTE PAIN · White paper
Acute Pain Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About acute pain — and why its trials are hard
Acute pain is sudden-onset, short-duration pain (typically under three months) triggered by surgery, injury, infection, or inflammation, serving as a protective warning signal. It arises from nociceptor activation and release of inflammatory mediators, but perception is strongly modulated by psychological state, prior pain experience, genetics (e.g., CYP2D6 affecting opioid metabolism), and culture. These features make acute-pain trials notoriously hard. The primary endpoint, pain intensity on the Visual Analog or Numeric Rating Scale, is entirely self-reported and highly variable between patients. Placebo response is large, diluting apparent drug effect. Because acute pain resolves quickly, the measurement window is narrow and assessment timing critical, risking underestimation of efficacy. Placebo-controlled designs raise ethical concerns when effective analgesia exists, and comorbidities plus concomitant medications confound results. Standardized validated models (dental extraction, bunionectomy, abdominoplasty), rescue-medication protocols, composite endpoints such as summed pain intensity difference, careful patient stratification, and enrichment strategies are used to generate interpretable, FDA-acceptable efficacy data while balancing opioid-sparing goals.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| suzetrigine (Journavx) | 2025 | moderate-to-severe acute pain in adults (first-in-class oral Nav1.8 inhibitor, non-opioid) | two Phase 3 studies (abdominoplasty and bunionectomy) | time-weighted summed pain intensity difference over 48 hours (SPID48) vs placebo | statistically superior to placebo on SPID48 in both trials; did not show superiority over hydrocodone/acetaminophen on a key comparison |
| celecoxib (Celebrex) | 1998 | acute pain, primary dysmenorrhea, osteoarthritis/RA (selective COX-2 inhibitor) | acute analgesic models (post-oral surgery, post-orthopedic, dysmenorrhea) | patient-rated pain intensity | significant pain relief within 60 minutes of a single dose vs placebo |
| tapentadol ER (Nucynta) | 2008 | moderate-to-severe pain requiring around-the-clock opioid (dual mu-opioid agonist + norepinephrine reuptake inhibitor) | chronic low back pain and diabetic peripheral neuropathy Phase 3 studies | 24-hour average pain severity on 11-point NRS | significantly greater pain reduction than placebo across studies |
| ibuprofen (IV) (Caldolor) | 1974 | acute pain and fever (non-selective NSAID; IV formulation) | post-hysterectomy and post-surgical analgesia studies | morphine consumption and pain intensity over 24 hours | significant reduction in mean morphine use (47 mg vs 56 mg) with greater pain-intensity reduction |
| oxycodone ER (OxyContin) | 1995 | moderate-to-severe pain needing continuous around-the-clock opioid analgesia | controlled clinical studies (label) | pain reduction on a pain-assessment scale | significant improvement with 20 mg vs placebo over 2 weeks (10 mg not significant) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in acute pain development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| tanezumab (anti-NGF) — NCT01089725 (osteoarthritis program) | FDA clinical hold in June 2010 halting dosing/enrollment; ultimately not approved | safety signal of rapidly progressive osteoarthritis and joint destruction outweighed analgesic benefit |
| fulranumab (anti-NGF) — NCT00973024 (PAI2003) | terminated for lack of efficacy | insufficient analgesic separation from control plus the class-wide NGF safety concerns that stalled the entire anti-NGF field |
| vixotrigine (BIIB074, Nav1.7 blocker) — GDCT0252702 | completed but ineffective in painful lumbosacral radiculopathy | safe but no efficacy signal, illustrating how high placebo response and heterogeneous pain populations defeat mechanistically promising analgesics |
Choosing the right endpoint
Primary endpoints that matter in acute pain trials
- Pain intensity reduction (VAS/NRS, SPID) — Primary efficacy measure, but self-reported and subjective; summed pain intensity difference over a fixed window (e.g., SPID48) reduces timing sensitivity.
- Time to onset of pain relief — Critical in acute settings, yet hard to measure precisely and must be balanced against fast-onset agents' adverse-effect risk.
- Rescue/opioid consumption — Opioid-sparing is a key regulatory and clinical goal; total rescue-analgesic use is an objective co-endpoint that complements subjective scores.
- Functionality and return to activity — Reflects real-world benefit but varies with baseline function and comorbidities, complicating interpretation.
- Safety/adverse-effect profile — Central to benefit-risk given opioid dependency, NSAID GI/renal/cardiovascular risk, and acetaminophen hepatotoxicity.
How iNGENū runs acute pain trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Acute Pain clinical trials — FAQs
Why is the placebo effect such a problem in acute-pain trials?
What makes suzetrigine (Journavx) significant?
Why did the anti-NGF analgesics like tanezumab fail to reach market?
Ready to discuss your acute pain trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal